Patient Engagement in the Early Drug Discovery Phase: The Role of Medical Affairs

Program Description:

While the value of patient engagement is increasingly recognized in the clinical and launch phases of drug development, it is still a relatively new concept to involve patients in the early discovery phase. By understanding the burden of disease and patient’s aspirations for new treatments from the outset, pharma companies can ensure they are developing medicines that matter to patients. As experts in the disease area and therapeutic landscape, Medical Affairs are well placed to initiate and develop effective patient partnerships to ensure that the patient voice is incorporated during early discovery and beyond.

In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.

Objectives:

1. Understand the need to engage with patients throughout the medicine development lifecycle, starting early during the discovery phase.
2. Explore approaches to patient engagement in early development to understand disease burden and develop target value profiles, through the use of case studies 
3. Highlight the critical role of Medical Affairs in initiating and developing patient partnerships at the discovery phase to ensure effective long-term collaborations
4. Gain awareness of resources and best practices to facilitate patient engagement in early drug development

Moderator:

Oleks Gobenko

Global Patient Centricity Director,

Ipsen

Speaker:

Dawn Lobban

Global Head, Envsion the Patient

Speaker:

Dawn Richards